Dichotomies in cancer research: Some suggestions for a new synthesis

Nature Clinical Practice Oncology

Volumn 3, Issue 7, 2006, Pages 364-373

  Sporn, Michael B ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Carcinogenesis; Chemoprevention; Epigenetics; Oncogenes; Reductionism

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; DELTANOID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; REXINOID DERIVATIVE; TRITERPENOID; UNCLASSIFIED DRUG;

BEHAVIOR MODIFICATION; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; CLINICAL PRACTICE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DNA DAMAGE; EPIGENETICS; GENE MUTATION; HEALTH CARE SYSTEM; HUMAN; LEUKEMIA; LUNG CANCER; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASM STAGING; NEOPLASMS; RISK FACTORS;

EID: 33745852174     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0536     Document Type: Review

References (95)

1. (online December 2005) Cancer Trends Progress Report-2005 Update [http://progressreport.cancer.gov] (accessed 17 May 2006)
2. Jemal A et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56: 106-130
3. Sporn MB (1996) The war on cancer: Lancet 347: 1377-1381
4. [No authors listed] (1999) Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res 59: 4743-4758
5. Sporn MB and Liby KT (2005) Cancer chemoprevention: Scientific promise, clinical uncertainty. Nat Clin Pract Oncol 2: 518-525
6. O'Shaughnessy JA et al. (2002) Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Clin Cancer Res 8: 314-346
7. Fisher B et al. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388
8. Martino S et al. (2004) Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96: 1751-1761
9. Fisher B et al. (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97: 1652-1662
10. Hruban RH et al. (2005) Identification and analysis of precursors to invasive pancreatic cancer. Methods Mol Med 103: 1-13
11. Maitra A et al. (2005) Precursors to invasive pancreatic cancer. Adv Anat Pathol 12: 81-91
12. Hingorani SR et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450
13. Urbina I (11 January 2006) In the treatment of diabetes, success often does not pay. The New York Times 155: A1, A26-A27
14. Feinberg AP and Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4: 143-153
15. Lund AH and van Lohuizen M (2004) Epigenetics and cancer. Genes Dev 18: 2315-2335
16. Laird PW (2005) Cancer epigenetics. Hum Mol Genet 14 (Spec No 1): R65-R76
17. Jones PA (2005) Overview of cancer epigenetics. Semin Hematol 42 (Suppl 2): S3-S8
18. Rauscher FJ III (2005) It is time for a Human Epigenome Project. Cancer Res 65: 11229
19. Nathan C (2002) Points of control in inflammation. Nature 420: 846-852
20. Coussens LM and Warb Z (2002) Inflammation and cancer. Nature 420: 860-867
21. Balkwill F et al. (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217
22. de Visser KE et al. (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37
23. Clark WH Jr (1995) The nature of cancer morphogenesis and progressive (self)-disorganization in neoplastic development and progression. Acta Oncol 34: 3-21
24. Grobstein C (1956) Inductive tissue interaction in development. Adv Cancer Res 4: 187-236
25. Grobstein C (1953) Inductive epitheliomesenchymal interaction in cultured organ rudiments of the mouse. Science 118: 52-55
26. Cunha GR et al. (1980) Induction of nuclear androgen-binding sites in epithelium of the embryonic urinary bladder by mesenchyme of the urogenital sinus of embryonic mice. Endocrinology 107: 1767-1770
27. Sakakura T et al. (1976) Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentiation in mouse mammary gland. Science 194: 1439-1441
28. Bissell MJ and Barcellos-Hoff MH (1987) The influence of extracellular matrix on gene expression: Is structure the message? J Cell Sci Suppl 8: S327-S343
29. Bissell MJ et al. (1982) How does the extracellular matrix direct gene expression? J Theor Biol 99: 31-68
30. Bhowmick NA et al. (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337
31. Bissell MJ et al. (2005) Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Siodrig Harb Symp Quant Biol 70: 1-14
32. Bates RR and Klein M (1966) Importance of a smooth surface in carcinogenesis by plastic film. J Natl Cancer Inst 37: 145-151
33. 1: From mutational spectrometry to carcinogenesis. Carcinogenesis 22: 535-545
34. Eaton DL and Gallagher EP (1994) Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol 34: 135-172
35. Marnett LJ et al. (2003) Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J Clin Invest 111: 583-593
36. Deininger M et al. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653
37. Tripathy D (2005) Targeted therapies in breast cancer. Breast J 11 (Suppl 1): S30-S35
38. Mitelman F et al. (1994) Catalog of Chromosome Aberrations in Cancer, edn 5. New York: Wiley-Liss
39. Loeb LA et al. (2003) Multiple mutations and cancer. Proc Natl Acad Sci USA 100: 776-781
40. Rabbitts TH (1994) Chromosomal translocations in human cancer. Nature 372: 143-149
41. Gorre ME and Sawyers CL (2002) Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 9: 303-307
42. Jordan VC (2006) Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 147 (Suppl 1): S269-S276
43. Suh N et al. (2001) Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 61: 8412-8415
44. Freemantle SJ et al. (2003) Retinoids in cancer therapy and chemoprevention: Promise meets resistance. Oncogene 22: 7305-7315
45. Wu K et al. (2002) The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62: 6376-6380
46. Suh N et al. (2002) Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res 8: 3270-3275
47. Yu X and Kensler T (2005) Nrf2 as a target for cancer chemoprevention. Mutat Res 591: 93-102
48. Darnell JE (2005) Validating Stat3 in cancer therapy. Nat Med 11: 595-596
49. Turkson J (2004) STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8: 409-422
50. Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740-749
51. Karin M and Greten FR (2005) NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759
52. Yates MS et al. (2006) Potent protection against aflatoxin-induced tumorigenesis through induction of nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res 66: 2488-2494
53. Giudice A and Montella M (2006) Activation of the Nrf2-ARE signaling pathway: A promising strategy in cancer prevention. Bioessays 28: 169-181
54. Jeong WS et al. (2006) Nrf2: A potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal 8:99-106
55. Kelly WK and Marks PA (2005) Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150-157
56. Marquez VE et al. (2005) Zebularine: A unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids 24: 305-318
57. Mintz B and Fleischman RA (1981) Teratocarcinomas and other neoplasms as developmental defects in gene expression. Adv Cancer Res 34: 211-278
58. Olive KP et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860
59. Lang GA et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119 861-872
60. Nilsson JA and Cleveland JL (2003) Myc pathways provoking cell suicide and cancer. Oncogene 22: 9007-9021
61. Aggarwal BB and Takada Y (2005) Pro-apototic and anti-apoptotic effects of tumor necrosis factor in tumor cells. Role of nuclear transcription factor NF-κB. Cancer Treat Res 126: 103-127
62. Wakefield LM and Roberts AB (2002) TGF-β signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12: 22-29
63. Siegel PM and Massague J (2003) Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 3: 807-821
64. Rowland BD and Peeper DS (2006) KLF4, ρ21 and context-dependent opposing forces in cancer. Nat Rev Cancer 6: 11-23
65. Smith CL and O'Malley BW (2004) Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25: 45-71
66. Strahl BD and Allis CD (2000) The language of covalent histone modifications. Nature 403: 41-45
67. Fischle W et al. (2003) Binary switches and modification cassettes in histone biology and beyond. Nature 425: 475-479
68. Janes KA et al. (2005) A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 310: 1646-1653
69. Nelson DE et al. (2004) Oscillations in NF-κB signaling control the dynamics of gene expression. Science 306: 704-708
70. Barrios-Rodiles M et al. (2005) High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307: 1621-1625
71. Colland F et al. (2004) Functional proteomics mapping of a human signaling pathway. Genome Res 14: 1324-1332
72. Stelzl U et al. (2005) A human protein-protein interaction network: A resource for annotating the proteome. Cell 122: 957-968
73. Bouwmeester T et al. (2004) A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nat Cell Biol 6: 97-105
74. Sanchez C et al. (1999) Grasping at molecular interactions and genetic networks in Drosophila melanogaster using FlyNets, an Internet database. Nucleic Acids Res 27: 89-94
75. Davies H et al. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591-7595
76. Moorehead A (1969) Darwin and the Beagle. New York: Harper & Row
77. Sporn MB (1991) Carcinogenesis and cancer: Different perspectives on the same disease. Cancer Res 51: 6215-6218
78. Haddow A (1972) Molecular repair, wound healing, and carcinogenesis: tumor production a possible overhealing? Adv Cancer Res 16: 181-234
79. Dvorak HF (1986) Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659
80. Prestera T et al. (1993) The electrophile counterattack response: protection against neoplasia and toxicity. Adv Enzyme Regul 33: 281-296
81. Holtzclaw WD et al. (2004) Protection against electrophile and oxidative stress by induction of phase 2 genes: The quest for the elusive sensor that responds to inducers. Adv Enzyme Regul 44: 335-367
82. Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780
83. Sporn MB and Suh N (2002) Chemoprevention: An essential approach to controlling cancer. Nat Rev Cancer 2: 537-543
84. Dinkova-Kostova AT et al. (2005) Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 102: 4584-4589
85. Liby K et al. (2005) The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 65: 4789-4798
86. Doroshow JH (2006) Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J Natl Cancer Inst 98: 223-225
87. Nathan C and Goldberg FM (2005) Outlook: The profit problem in antibiotic R&D. Nat Rev Drug Discov 4: 887-891
88. Nathan C (2004) Antibiotics at the crossroads. Nature 431: 899-902
89. Zweig P (1985) The wound-dresser. In Walt Whitman, 143-157 (Ed Bloom H) New York: Chelsea House Publishers
90. Leaf C (2005) The law of unintended consequences. In Fortune, September 19 2005, 250-268
91. Hutchinson L and DeVita VT Jr (2005) Herceptin: HERalding a new era in breast cancer care but at what cost? Nat Clin Pract Oncol 2: 595
92. Berenson A (15 February 2006) A cancer drug shows promise, at a price that many can't pay. The New York Times 155: A1, C2
93. Lyall S (16 February 2006) British clinic is allowed to deny medicine. The New York Times 155: A6
94. Billington DP (2003) The Art of Structural Design: A Swiss Legacy. New Haven: Princeton University Art Museum and Yale University Press.
95. McCarter R (2005) Louis Kahn. London and New York: Phaidon Press.